---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-011975"
form_type: "8-K"
ticker: "GCTK"
cik: "0001506983"
company_name: "Glucotrack, Inc."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T13:07:00.856674+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Glucotrack H1 net loss $11.6M; cash $9.6M; on track to implant first CBGM patients in Australia Q3 2025

## Summary
- Net loss of $11.6M for H1 2025 vs $7.4M prior year; operating expenses rose $0.9M.
- Cash and equivalents $9.6M as of June 30, 2025, expected to fund operations through 2025.
- Received ethical approval in Australia; first patient implants in multicenter feasibility study expected Q3 2025.
- Repurchased Series A warrants, eliminating warrant liability accounting and dilution overhang.
- Positive first-in-human CBGM data reported: MARD 7.7%, 99% data capture, no serious adverse events.

## SEC filing metadata
- accession: 0001493152-25-011975
- form_type: 8-K
- ticker: GCTK
- cik: 0001506983
- company_name: Glucotrack, Inc.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506983/000149315225011975/0001493152-25-011975-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506983/000149315225011975/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-011975
- JSON: https://secwatch.observer/filing/0001493152-25-011975.json
- Plain text: https://secwatch.observer/filing/0001493152-25-011975.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.